Introduction
============

MicroRNAs (miRNAs) are defined as endogenous small and non-coding RNAs that are approximately 18-24 nucleotides in length and play a significant role in the regulation of gene expression ([@B1]). These non-coding RNAs are negative regulators of gene expression ([@B2]). MiRNAs may have roles not only as oncogenes but also as tumor suppressors, further suggesting them as therapeutic targets ([@B3]). The interaction between miRNAs and 3´-nontranslatable regions of target mRNAs by complementarity, triggers mRNA degradation or prevents its translation ([@B2], [@B4]). As of today, more than 2000 different miRNAs have been characterized ([@B2]). MiRNAs could be considered as a valuable diagnosis or prognosis biomarker to predict the likely outcome of certain diseases such as cancer ([@B5]).

Glioma as one of the main central nervous system (CNS)-related cancers, comprises nearly 30% of all brain and CNS tumors and 80% of all malignant brain tumors ([@B6]). miR-126 is found on chromosome 9 within intron 7 of epidermal growth factor like domain 7 (*EGFL7*) gene ([Fig .1](#F1){ref-type="fig"}) ([@B7]). miR-126 is one of the most important miRNAs that has significant roles in cellular biology, including cancer biology. Schmidt and colleagues showed that miR-126 is mainly involved in angiogenesis and inflammation, and briefly reviewed that miR-126 may play crucial roles in several human cancers ([@B8]).

In this regard, a number of miR-126 target genes has already been characterized. *EGFL7* is the host gene of miR-126, which is also the major target of miR 126. Transcription of *EGFL7* and miR-126 occurs simultaneously and mature miR-126 matches with a complementary sequence within the host gene *EGFL7*, causing a decrease in EGFL7 protein levels and activating a negative feedback mechanism. EGFL7 affects cell migration pathways by interfing with tissue invasion and angiogenesis. Negative feedback mechanism of miR-126 shows that one of the main functions of miR-126 is regulating EGFL7 protein formation, leading to reduction of angiogenesis and cell migration ([@B9]).

![Structural organization and products of the EGFL7 gene. The EGFL7 gene contain 10 exons, but only exons 3-9 encode for the EGFL7 protein, which exhibits a modular structure with an N-terminal signal secretion peptide (SS) followed by an Emilin-like domain (EMI), two epidermal growth factor-like domains (EGF), and a coiled-coil (CC) region. A premiRNA structure is placed in intron 7 of the EGFL7 gene from which miR126 and miR-126\* originate ([@B8]).](Cell-J-20-150-g01){#F1}

Another target of miR-126 is insulin receptor substrate-1 (IRS-1) as upregulation of miR-126 can significantly inhibit the expression of IRS-1 ([@B10]). IRS-1 is able to modify PI3K/Akt signalling through neurotrophin pathway which is one of the major pathways involved in neural cell differentiation ([@B11]). Furthermore, V-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is considered another target gene of miR-126. KRAS is involved in cellular differentiation via PI3K/Akt pathway ([@B12]). Interestingly, Ras and PI3K proteins are associated with the glioma cancer cells formation through Notch, Hedgehog (Hh), Wnt/betacatenin, and focal adhesion pathways ([@B13]). Therefore, upregulation of miR-126 may suppress IRS-1 and subsequently trigger the formation of glioma cancer stem cell ([@B14]).

Cancer progression needs permanent formation of blood vessels to nourish the cancer cells. Thus, controlling this factor is of immense importance in inhibition of cancer progression ([@B15]). Furthermore, miR-126 can affect many cellular mechanisms involved in cancer pathogenesis via suppressing translation of numerous validated target gene such as *PI3K, KRAS, EGFL7, CRK, ADAM9, HOXA9, IRS-1, SOX-2, SLC7A5* and *VEGF* in colorectal, gastric, oesophageal, oral, pancreatic, liver, thyroid, breast, cervical, ovarian, prostate, bladder, renal, and lung cancers as well as melanoma, osteosarcoma and leukemia ([@B16]). We here used molecular signaling pathway enrichment analysis to determine possible associations between miR-126 and IRS1 within neurotrophin pathway, for the first time.

Materials and Methods
=====================

In this prospective study, all miRNA-mRNA prediction analyses were conducted by miRWalk 2.0 database (zmf.umm.uni-heidelberg.de/apps/zmf/ mirwalk2/) which is an integrative mRNA-miRNA prediction database ([@B17]). In order to find validated interactions, we implemented miRtarbase database (*http://mirtarbase.mbc.nctu.edu.tw/*) which provides experimentally validated mRNA-miRNA interactions from all previously performed studies ([@B18]).

Then, approximate expression of miR-126 targeting in glioma tissue was examined using UniGene database (*http://www.ncbi.nlm.nih.gov/unigene*). Finally, in silico molecular pathway enrichment analysis was carried out by DAVID 6.7 database (*http://david.abcc. ncifcrf.gov/*) ([@B19]) to explore which signaling pathway is related to miR-126 targetome and how miR-126 attributes to the formation of glioma. This database utilized the P values associated with each annotation terms inside each cluster are exactly the same meaning/ values as those (Fisher's Exact/EASE Score) shown in the regular chart reported for the same terms.

Results
=======

At the first step, in order to find the predicted target genes of miR-126, miRWalk 2.0 was implemented. Approximately 111 target genes were predicted to be the potential targets of miR-126. Moreover, 24 genes were also validated to be the target genes of miR-126. The predicted target could be the potential targets of miR-126 reported by miRWalk database. Checking DAVID database showed the involvement of miR-126 target genes in several signaling pathways indicated by the KEGG database including cancer pathway, neurotrophin signaling pathway, glioma, insulin signaling pathway, focal adhesion, chemokine signaling pathway and regulation of actin cytoskeleton ([Table 1](#T1){ref-type="table"}). Also, validated target genes of miR-126 were extracted from mirtarbase ([Table 2](#T2){ref-type="table"}) and predicted target genes of miR-126 were obtained from miRWalk 2.0 ([Table 3](#T3){ref-type="table"}).

Fisher's exact test P values and enrichment scores \[corresponding to false discovery rate (FDR)\] were calculated to characterize the gene groups enriched in the target list. According to the results, *PIK3R2, KRAS, CRK* and *IRS1* were involved in the different pathways mentioned above and were targeted by miR-126. Furthermore, the target genes, were experimentally validated.

Our evaluation determined that some KEGG pathways ([Table 1](#T1){ref-type="table"}) including neurotrophin ([Fig .2](#F2){ref-type="fig"}) and focal adhesion signaling pathways ([Fig .3](#F3){ref-type="fig"}) are the ones that are most statistically associated with miR 126 targeting. Interestingly, four genes namely, *KRAS, PIK3R2, IRS1* and *CRK* were influenced by miR 126. Among them, *PIK3R2* and *KRAS* were shown to be the most effective genes in focal adhesion and neurotrophin pathways.

###### 

The KEGG pathways reported by DAVID, concerning miR-126 targets based on TarBase 6.0

  ------------------------------------------- ------- ------ ---------- ----------- ------------------------------------------------------------
                                                                                    
  Signaling pathway                           Count   \%     P value    FDR         Genes
                                                                                    
  Neurotrophin signaling pathway              8       6.15   0.000035   0.036985    1398, 10818, 2309, 3667, 3845, 8660, 4792, 5296
  Insulin signaling pathway                   6       4.61   0.0034     3.5688779   1398, 7248, 3667, 3845, 8660, 5296
  Aldosterone-regulated sodium reabsorption   4       3.07   0.0036     3.798433    3667, 3845, 8660, 5296
  Prostate cancer                             7       5.38   0.00005    0.052897    3480, 9134, 1869, 3845, 1027, 4792, 5296
  Chronic myeloid leukemia                    6       4.61   0.00024    0.252281    1398, 1869, 3845, 1027, 4792, 5296
  Small cell lung cancer                      6       4.61   0.0004     0.428764    9134, 1869, 1027, 4792, 3655, 5296
  Pathways in cancer                          10      7.69   0.00065    0.691123    1398, 3480, 9134, 1869, 7422, 3845, 1027, 4792, 3655, 5296
  Chemokine signaling pathway                 7       5.38   0.0027     2.838854    1398, 6387, 2309, 7852, 3845, 4792, 5296
  Non-small cell lung cancer                  4       3.07   0.0079     8.08554     1869, 2309, 3845, 5296
  Glioma                                      4       3.07   0.012      12.1033     3480, 1869, 3845, 5296
  Renal cell carcinoma                        4       3.07   0.016      15.78153    1398, 7422, 3845, 5296
  Melanoma                                    4       3.07   0.017      16.34347    3480, 1869, 3845, 5296
  Pancreatic cancer                           4       3.07   0.017      16.91404    1869, 7422, 3845, 5296
  ErbB signaling pathway                      4       3.07   0.028      26.3737     1398, 3845, 1027, 5296
  Type II diabetes mellitus                   3       2.3    0.05       41.96915    3667, 8660, 5296
  Focal adhesion                              5       3.84   0.066      51.80995    1398, 3480, 7422, 3655, 5296
  Endometrial cancer                          3       2.3    0.066      48.06802    2309, 3845, 5296
  Colorectal cancer                           3       2.3    0.14       78.64442    3480, 3845, 5296
  Progesterone-mediated oocyte maturation     3       2.3    0.14       79.97993    3480, 3845, 5296
  Regulation of actin cytoskeleton            4       3.07   0.23       93.51759    1398, 3845, 3655, 5296
                                                                                    
  ------------------------------------------- ------- ------ ---------- ----------- ------------------------------------------------------------

FDR; False discovery rate. miR-126 target genes in several signaling pathways such as pathways in cancer, neurotrophin signaling pathway, glioma, insulin signaling pathway, focal adhesion, chemokine signaling pathway and regulation of actin cytoskeleton, etc.

###### 

Targets of hsa-miR-126 validated by mirTarbase

  ------------- ---------------- ----------- ------------
                                             
  Hsa-miR-126   Enterz gene ID   Brain^\*^   Glioma^\*^
                                             
  SPRED1        161742           36          37
  PLK2          10769            388         121
  CCNE2         9134             27          37
  RGS3          5998             69          74
  TOM1          10043            178         102
  CRK           1398             83          83
  VEGFA         7422             52          158
  PIK3R2        5296             70          279
  VCAM1         7412             20          0
  IRS1          3667             11          27
  E2F1          1869             18          55
  SOX2          6657             70          429
  TWF1          5756             38          55
  TWF2          11344            51          74
  DNMT1         1786             48          74
  KRAS          3845             32          9
  IGFBP2        3485             84          457
  PITPNC1       26207            34          46
  MERTK         10461            12          46
  EGFL7         51162            20          37
  SLC7A5        8140             48          65
  TEK           7010             40          0
  ADAM9         8754             21          37
  CXCL12        6387             44          0
  FOXO3         2309             80          121
  CXCR4         7852             34          27
  CD97          976              52          83
  TCF4          6925             187         93
  Cdkn1b        1027             173         46
  RHOU          58480            58          93
  LRP6          4040             19          9
  ADM           133              42          158
  NFKBIA        4792             48          167
                                             
  ------------- ---------------- ----------- ------------

\*; Transcripts per million (TPM).

###### 

A part of targets of hsa-miR-126 predicted by mirWalk2

  --------- ---------- ----------- ------------
                                   
  Gene      EntrezID   Brain^\*^   Glioma^\*^
                                   
  PTPN9     5780       27          93
  SOX2      6657       70          429
  GOLPH3    64083      119         111
  PEX5      5830       73          55
  RGS3      5998       69          74
  UBQLN2    29978      57          102
  SPRED1    161742     36          37
  CRK       1398       48          37
  ITGA6     3655       31          27
  IRS1      3667       11          27
  LRP6      4040       19          9
  SLC7A5    8140       48          65
  HERPUD1   9709       86          167
  PLK2      10769      388         121
  SOX21     11166      13          74
  GATAD2B   57459      32          18
  ORMDL3    94103      37          83
  ANTXR2    118429     25          0
  PKD2      5311       21          9
  PLXNB2    23654      64          74
  FOXO3     2309       80          121
  IGF1R     3480       36          102
  QDPR      5860       374         65
  SDC2      6383       115         55
  IRS2      8660       37          121
  LARGE     9215       39          46
  TOM1      10043      178         102
  MGEA5     10724      182         83
                                   
  --------- ---------- ----------- ------------

\*; Transcripts per million (TPM).

![miR-126 is involved in neurotrophin signaling pathway pathways including IRS1, PI3K and IκB, which their partial diagram collected from KEGG pathway is demonstrated. Red stars mark targets of miR-126.](Cell-J-20-150-g02){#F2}

![Involvement of miR-126 targetome in focal adhesion signaling pathway from KEGG is shown. miR-126 target genes are determined by red star marks.](Cell-J-20-150-g03){#F3}

Discussion
==========

So far, MiR-126 is the only characterized miRNA that shows endothelial cell (EC)-specific expression and the first vascular miRNA that was knocked out in mice. Loss- of-function studies in mice and zebrafish showed that miR126 possesses an important function in controlling vascular integrity and angiogenesis ([@B17], [@B18]). Previous studies indicated truncation of miR-126 in mouse as a pathogenic cause of leaky vessels, hemorrhage, and embryonic death, due to loss of vascular integrity and defective angiogenesis. *miR-126^-/-^* mice demonstrated severely hindered vascularization during development of cranial vessel and retina. In addition, *miR-126^-/-^* showed defective angiogenesis in response to angiogenic factors ([@B19]).

Knockdown of miR-126 in zebrafish led to hemorrhage, and collapse of the dorsal aorta and primary cardinal veins, indicating a conserved function of miR-126. In vivo functional studies in mice and zebrafish showed a function for *Egfl7*(as the host gene of miR-126) in EC migration and vasculogenesis ([@B20], [@B21]). Interestingly, edema, defective cranial vessel and retina vascularization were the signs for *miR-126^-/-^* mice as well as *Egfl7^-^* knockout mice. The molecule responsible for the observed phenotype has been discussed. However, in *miR-126^-/-^* mice, *Egfl7* expression was not altered ([@B21]). Nonetheless, miR-126 expression in *Egfl7^-^* knockout mice was not reported ([@B22]). Recently, floxed alleles of *Egfl7 (Egfl7^Δ^)* and miR-126 (*miR-126^Δ^*) were generated ([@B23]).

*Egfl7^Δ/Δ^* mice, in which miR-126 expression is not affected, are phenotypically normal whereas *miR-126^Δ/Δ^* mice, in which *Egfl7* is normally expressed, exhibit numerous previously explained embryonic and postnatal vascular phenotypes observed in *Egfl7*-knockout mice. These results indicated that miR-126 is an essential factor not only for angiogenesis but also for maintenance of vascular integrity. The in vivo functions of Egfl7 might be supported by its paralog Egfl8. This debate highlights the significance of minimally disruptive gene-targeting strategies because of the presence of intronic miRNAs in the genome. Neoangiogenesis is important for vascular regeneration in response to injury, such as myocardial infarction (MI).

*miR-126^-/-^* mice also exhibited reduced survival and defective cardiac neovascularization following MI, suggesting a significant role for miR-126 in neoangiogenesis ([@B24]). Previous reports have indicated that proangiogenic function of miR-126 is exerted through enhancement of MAP kinase and PI3K signaling in response to vascular endothelial growth factor (VEGF) and fibroblast growth factors (FGF) ([@B20]). Also, Saito et al. ([@B25]) examined alterations in epigenetic and expression levels of miR-126 in human cancer cells. Therefore, it seems that epigenetic modifications may control the expression of miR-126 as a tumor suppressor intronic miRNA through directly controlling the host target gene, EGFL7 ([@B26]). Apart from Spred-1, PIK3R2 and EGFL7, miR-126 targets vascular cell adhesion protein 1 (VCAM-1), thereby affects the regulation of the adhesion of leukocytes to the endothelium ([@B27]) defining another role for miR-126 in vascular inflammation. It was also reported that MiR-126 prevents tumorigenesis and is downregulated in many cancer lines ([@B25], [@B26], [@B28]).

Importantly, PIK3R2 and CT10 regulator of kinase (CRK) showed to be the targets for miR-126 in cancer cells ([@B28]). Evidence showing that PIK3R2 represses PI3KAKT signaling in ECs but enhances PI3K-AKT signaling in cancer cells, is not sufficient. Nevertheless, these results indicate that miR-126 is a multi-functional miRNA with important roles in angiogenesis, tumor growth and invasion, and vascular inflammation ([@B29]). Another target of miR-126 was revealed by Zhang et al. ([@B10]). They showed that miR-126 prevented cell cycle progression in breast cancer cells via targeting IRS-1 at 3\'-UTR ([@B8]). Also, miR-126 targets *HOXA9*; the overexpression of *HOXA9* is associated with poor prognosis in acute myelogenous leukemia ([@B26]). These studies showed that miR-126 plays a significant role in tumorigenesis, tumor progression and metastasis ([@B22], [@B28]).

Neurotrophins form a family of growth factors which play significant roles in neuronal development. This family has four members in mammals: i. Brain-derived neurotrophic factor (BDNF), ii. Nerve growth factor (NGF), iii. Neurotrophin-3 (NT3), and iv. Neurotrophin-4/5 (NT4/5) ([@B30]). Neurotrophins are synthesized as larger precursors which undertake proteolytical cleavage for production of mature neurotrophins. These factors perform multiple functions in the nervous system. As they may raise survival, differentiation, axon outgrowth or apoptosis ([@B31], [@B32]).

Barker indicated that dependingon the type of neurotrophin and the expression pattern of neurotrophin receptors (NTRs), neurotrophin is triggered by binding to two different classes of cell surface receptors namely, p75NTR and Trk receptors. The Trk receptors (TrkA, TrkB, and TrkC) comprise a large family of receptor tyrosine kinases, whereas p75NTR is structurally a member of the Fas/TNF-R family ([@B33], [@B34]). In primary cultures of rodent superior cervical ganglion sympathetic neurones, the TrkA ligands, NGF and NT3 enhance survival and neurite outgrowth during embryonic development, whereas the p75NTR ligand, BDNF has been reported to induce apoptosis ([@B35]). Evangelopoulos et al. ([@B36]) showed that TrkB-Fc or TrkC-Fc receptors are useful tools for modification of the survival of neuroblastoma cells.

Ahn et al. ([@B11]) showed that glioma invasion mediated by the p75 neurotrophin receptor (p75NTR/CD271), requires regulated interaction with PDLIM1 (a member of the ALP subfamily of PDZ/LIM proteins). Wadhwa et al. ([@B37]) suggested that Trk A and Trk B are involved in early stages of tumor pathogenesis, glial proliferation, and progression of malignancy. Lawn et al. ([@B38]) and Forsyth et al. ([@B39]) proved that neurotrophin signaling pathway promotes the growth and proliferation of glioma cell line. Li et al. ([@B40]) confirmed that different mechanisms found for regulations of NDAP (neurotrophin-regulated neuronal development-associated protein) expression by neurotrophins, might be checkpoints for apoptosis during neuronal development.

Conclusion
==========

Our results suggested a significant role for neurotrophin signaling pathway in gliomagenesis. According to our findings, overexpression of miR-126 may lead to downregulation of IRS-1 and subsequently formation of glioma cancer stem cell.
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